ATE303154T1 - Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv - Google Patents

Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Info

Publication number
ATE303154T1
ATE303154T1 AT00971704T AT00971704T ATE303154T1 AT E303154 T1 ATE303154 T1 AT E303154T1 AT 00971704 T AT00971704 T AT 00971704T AT 00971704 T AT00971704 T AT 00971704T AT E303154 T1 ATE303154 T1 AT E303154T1
Authority
AT
Austria
Prior art keywords
trifluridine
hiv
phosphorylase inhibitor
thymidine phosphorylase
treatment
Prior art date
Application number
AT00971704T
Other languages
English (en)
Inventor
Hiroo Hoshino
Kenji Kitazato
Masakazu Fukushima
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE303154T1 publication Critical patent/ATE303154T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00971704T 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv ATE303154T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31567099A JP4110347B2 (ja) 1999-11-05 1999-11-05 抗ｈｉｖ剤
PCT/JP2000/007676 WO2001034162A1 (fr) 1999-11-05 2000-11-01 Compositions anti-vih

Publications (1)

Publication Number Publication Date
ATE303154T1 true ATE303154T1 (de) 2005-09-15

Family

ID=18068171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971704T ATE303154T1 (de) 1999-11-05 2000-11-01 Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv

Country Status (6)

Country Link
US (1) US6596720B1 (de)
EP (1) EP1230925B8 (de)
JP (1) JP4110347B2 (de)
AT (1) ATE303154T1 (de)
DE (1) DE60022380T2 (de)
WO (1) WO2001034162A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025575A1 (en) * 2001-09-17 2003-03-27 Board Of Regents, The University Of Texas System Methods and compositions involving thymidine phosphorylase as a marker for hiv infection, aids progression, and drug resistance
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
CN101484443B (zh) 2006-06-30 2012-11-21 大鹏药品工业株式会社 放射线治疗增强剂
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
PT2368555T (pt) * 2007-01-31 2016-07-25 Biosuccess Biotech Company Composições e métodos de utilização de ésteres de forbol
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
TWI429439B (zh) * 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI585206B (zh) 2012-03-14 2017-06-01 Nisshin Pharma Inc A method for producing a composition containing a sulfur-containing amino acid
SG10202007643SA (en) 2013-06-17 2020-09-29 Taiho Pharmaceutical Co Ltd Stable crystal form of tipiracil hydrochloride and crystallization method for the same
CN103980253B (zh) * 2014-05-06 2015-07-08 济南百诺医药科技开发有限公司 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法
CN106317028A (zh) * 2015-11-03 2017-01-11 江苏悦兴药业有限公司 抗肿瘤药物盐酸替比拉西的制备方法及其关键中间体
CN112569250A (zh) * 2020-10-16 2021-03-30 中山大学 三氟尿苷制备hiv-1药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3469533D1 (en) * 1983-05-23 1988-04-07 Taiho Pharmaceutical Co Ltd Novel 2'-deoxy-5-substituted uridine derivatives, processes for preparing the same and antitumor agent containing the same
EP0258412A1 (de) * 1986-02-20 1988-03-09 GREER, Sheldon B. Zubereitung und verfahren zur behandlung von aids und verwandten krankheiten
ATE72122T1 (de) * 1987-04-24 1992-02-15 Wellcome Found Antivirale mischungen.
CA2033447C (en) * 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
CA2033448C (en) * 1990-12-31 1996-11-26 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes compositions and method of use
JP3088757B2 (ja) * 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
JP4049477B2 (ja) * 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤

Also Published As

Publication number Publication date
WO2001034162A1 (fr) 2001-05-17
JP2001131075A (ja) 2001-05-15
EP1230925A4 (de) 2004-06-09
DE60022380T2 (de) 2006-06-08
US6596720B1 (en) 2003-07-22
EP1230925A1 (de) 2002-08-14
DE60022380D1 (de) 2005-10-06
EP1230925B8 (de) 2006-03-01
JP4110347B2 (ja) 2008-07-02
EP1230925B1 (de) 2005-08-31

Similar Documents

Publication Publication Date Title
DE60022380D1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin-phosphorylase-hemmer zur behandlung von hiv
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
HN1996000017A (es) Isotiazolonas
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69316751D1 (de) Azlaktonfunktionen aufweisende substrate, hornhautprothesen und ihre verwendung
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
ATE229272T1 (de) Desinfizierende zusammensetzung auf basis von h2o2, säuren und metallionen
BR9902457A (pt) Padrões de adesivo aperfeiçoados para artigos de higiene feminina.
DE69403656D1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE438361T1 (de) Stent beschichtet mit dna
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ATE275824T1 (de) Antiadhäsive sterole und sterolderivate
WO2003090674A3 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
EE200100032A (et) Ühendid, kompositsioonid ja meetodid neuronaalse kasvu ja elongatsiooni stimuleerimiseks
DE69015411D1 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties